Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs
Overview
Diabetic cardiomyopathy (DCM) is a distinct clinical entity of diabetic heart muscle that describes diabetes associated changes in the structure and function of the myocardium in the absence of coronary artery disease, hypertension, and valvular disease. Oxidative stress plays a critical role in DCM development. DCM can be diagnosed using the novel methods of echocardiography (tissue Doppler imaging, Speckling tracking techniques and more recent real time 4D echocardiography). There is a possible cardioprotective effect of statins, Captopril and L-Carnitine in type 1 diabetic children and adolescents.
Full Title of Study: “Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardio-protective Drugs”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Double (Participant, Outcomes Assessor)
- Study Primary Completion Date: June 1, 2019
Interventions
- Drug: Atorvastatin
- cardio-protective agents
- Drug: Captopril
- cardio-protective agents
- Drug: L-carnitine
- cardio-protective agents
Arms, Groups and Cohorts
- No Intervention: diabetic- no cardioprotectives
- 25 child with type 1 diabetes mellitus will not receive any cardio protective drug
- Experimental: diabetic-Atorvastatin
- 25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
- Experimental: diabetic-Captopril
- 25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
- Experimental: diabetic-L-Carnitine
- 25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
- No Intervention: Controls
- 50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
Clinical Trial Outcome Measures
Primary Measures
- The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.
- Time Frame: before and after 4 months of receiving cardio-protective agents
- Corrected QT interval(QTc) and QT dispersion in ElectroCardioGram
- The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.
- Time Frame: before and after 4 months of receiving cardio-protective agents
- Left Ventricular End Systolic Volume (ml). Left Ventricular End Diastolic Volume (ml). Ejection Fraction (EF %) and left ventricular strain using echocardiography.
Secondary Measures
- The role of Troponin I levels as a cardiac marker for detection of asymptomatic cardiovascular insult in diabetic children.
- Time Frame: first day
- Serum Cardiac troponin I by Enzyme Linked ImmunoSorbant Assay
- The role of recent echocardiographic parameters for early detection of silent myocardial dysfunction
- Time Frame: first day
- Echocardiography
- Identification of risk factors for developing diabetic cardiac insult.
- Time Frame: first day
Participating in This Clinical Trial
Inclusion Criteria
- Children and adolescent suffering from type 1 Diabetes Mellitus, for at least 3 years from the onset of the disease. Exclusion Criteria:
- Children with Congenital Heart Diseases. – Children with acquired cardiac diseases. – Children with other systemic diseases. – Symptomatic diabetic cardiomyopathy.
Gender Eligibility: All
Minimum Age: 3 Years
Maximum Age: 18 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Tanta University
- Provider of Information About this Clinical Study
- Principal Investigator: Rasha Mohamed Gamal, Ass. Professor of Pediatrics – Tanta University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.